Answers are grounded in this paper and cite their sources.
Psoriasis is a chronic, inflammatory skin disease, whose onset may occur at any age.1 The literature is constantly being updated with reports of studies investigating the use of systemic treatments in geriatric patients with psoriasis.1 However, long‐term treatment of psoriasis is often complicated in elderly patients as they frequently have several comorbidities, an increased risk of developing infections and cancers, and polypharmacy.1 2 Therefore, traditional systemic therapies are often contraindicated or highly risky, highlighting the frequent need for shifting to biologics [anti‐tumour necrosis factor (TNF)‐α or anti‐interleukin (IL)‐12/23]. However, the efficacy and safety of biologics in patients ≥ 65 years are not clearly described because such patients are rarely enrolled in clinical trials. Although there are some data available for anti‐TNF‐α use,3 4 more studies are needed for anti‐IL‐12/23 (ustekinumab).5 Therefore, we sought to evaluate the efficacy and safety of ustekinumab in a group of elderly patients with psoriasis over a 2‐year period. We performed a retrospective study on patients aged ≥ 65 years treated with ustekinumab for at least 2 years during the period 2011–2014, collecting data from a computer database of the psoriasis care centre of University of Naples Federico II, Italy. In all cases, ustekinumab was administered subcutaneously (45 mg for patients < 100 kg and 90 mg for subjects > 100 kg) at weeks 0, and 4, and then every 12 weeks during the treatment period. Each patient underwent regular clinical follow‐up [including assessment of Psoriasis Area Severity Index (PASI) and body surface area] and blood tests (full blood count, glucose, urea, creatinine, erythrocyte sedimentation rate, C‐reactive protein, aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyl transpeptidase, cholesterol, triglycerides, protein electrophoresis) every 3 months. The safety profile of ustekinumab was evaluated by monitoring adverse events, including their severity and relationship to the drug and by assessing physical examinations, clinical laboratory parameters and vital signs at each follow‐up visit. The study population was represented by 22 elderly patients with psoriasis (15 men and 7 women, mean age 70.39 ± 4.6 years) (Table 1). Hypertension was the most frequent comorbidity (n = 14, 63.6%), followed by dyslipidaemia (n = 6, 27.3%) and diabetes (n = 5, 22.7%). In total, 68.2% of subjects (n = 15) had already been treated with ciclosporin, 59.1% (n = 13) with methotrexate, and 54.5% (n = 12) with biologics (Table 1). Mean PASI was 13.7 ± 5.1 (range 5.4–28.2) at baseline, which reduced to 1.9 ± 2.5 (range 0–8.4) after 52 weeks and 0.7 ± 1.2 (range 0–4.5) after 100 weeks of treatment. PASI 75 was reached in 63.6% (n = 14), 86.4% (n = 19) and 90.9% (n = 20) of patients after 28, 52 and 100 weeks, respectively (Fig. 1); these results were better than those of Hayashi et al. who observed PASI 75 in only 60% of patients after 52 weeks of treatment.5 Data on demographics, comorbidities, psoriasis severity and previous treatments in the study population NB‐UVB, narrowband ultraviolet B. *Data are mean ± SD (range) unless otherwise stated; †Adalimumab : etanercept : infliximab: 6 : 8 : 2. Data on demographics, comorbidities, psoriasis severity and previous treatments in the study population NB‐UVB, narrowband ultraviolet B. *Data are mean ± SD (range) unless otherwise stated; †Adalimumab : etanercept : infliximab: 6 : 8 : 2. Psoriasis Area Severity Index (PASI) 50, 75, 90 and 100 results after 28, 52, 76 and 100 weeks of treatment. During the 2‐year, no cases of serious infections were reported; only two mild adverse events were registered (one liver enzyme elevation and one hyperglycaemia) suggesting that the safety and tolerability profiles of ustekinumab are very favourable even in such a particular class of patients, which confirms the results of Hayashi et al.5 but in an extended monitoring period of up to 2 years. In conclusion, the results of our study showed that ustekinumab had an adequate efficacy and safety profile over a 2‐year treatment period in elderly patients with psoriasis. One limitation of our study is that the sample size was small, which may limit the generalizability of our results. Further studies with larger numbers are warranted to confirm our results. Conflict of interest: the authors declare that they have no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Megna et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: